Compare Amphastar Pharmaceuticals Inc (AMPH) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs QUALCOMM, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while QUALCOMM, Inc. trades at $184.9 (market cap $199.37B). The key difference: QUALCOMM, Inc. is far larger — about 241.3× Amphastar Pharmaceuticals Inc's market cap, and QUALCOMM, Inc. pays a 1.95% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | QCOM | |
|---|---|---|
Market Cap | $826.08M | $199.37B |
Sector | Health | Technology |
52-Week High | $30.81 | $251.10 |
52-Week Low | $16.87 | $124.07 |
Enterprise Value | $1.22B | $204.85B |
Dividend Yield | — | 1.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Qualcomm (QCOM) trades at $189.16, down 1.01% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported revenue of $44.28 billion in 2025, with a net income margin of 22.31% and robust cash flow from operations of $14.01 billion. Recent news highlights its push into AI and data centers, though competition from Nvidia in the PC chip market poses challenges.
The outlook for QCOM is positive, driven by diversification into automotive and AI, with a consensus price target of $221.21 implying 17% upside. Risks include smartphone market softness and margin pressures, but strong analyst buy ratings (42.65%) and institutional support suggest confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
